Tranxizin 2 mg

Produkt Beschreibung

1. Classification and Chemical Overview

Trankimazin 2mg is the primary branded pharmaceutical preparation of alprazolam marketed in Spain and select European regions by Viatris (formerly Pfizer / Upjohn). Chemically designated as $8\text{-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine}$, alprazolam is a high-potency synthetic psychoactive compound belonging to the triazolobenzodiazepine chemical class. Structurally, it features a core 1,4-benzodiazepine nucleus fused with a methylated triazole ring at the 1,2-position, which enhances binding affinity at specific central receptor complexes and alters hepatic metabolic routing compared to classical benzodiazepines. Its empirical molecular formula is $\text{C}_{17}\text{H}_{13}\text{ClN}_4$, with an average molecular weight of $308.76\text{ g/mol}$.

Standard solid oral presentations of Trankimazin 2mg appear as white, elongated, rectangular scored tablets (commonly referred to colloquially across international markets as “bars” or “barras”). The tablets feature three transverse score lines dividing them into four breakable sections, each delivering $0.5\text{ mg}$ of active alprazolam base. Conventional pharmaceutical excipients include lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, maize starch, sodium docusate, sodium benzoate, and magnesium stearate.

Within the United Kingdom and international regulatory frameworks:

• UK Classification: Alprazolam is categorized as a Prescription Only Medicine (POM) governed by the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971 and Misuse of Drugs Regulations 2001, alprazolam is scheduled as a Class C, Schedule 4 (Part 1 / CD Benz POM) controlled substance. It is not available on the NHS for routine primary care prescription and is absent from standard NHS FP10 prescribing formularies; in the UK, it is accessible almost exclusively via private, specialized psychiatric prescription or imported under specific MHRA “specials” procurement arrangements.

• Spanish / European Status (AEMPS): Authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS) as a prescription-only medicinal product subjected to national psychotropic control regulations (medicamento sujeto a prescripción médica – psicótropo).

Due to its high commercial recognition, Trankimazin 2mg is heavily targeted by international counterfeit operations and diverted across European and UK grey markets. Forensic testing of illicit “Trankimazin 2mg” bars routinely detects complete absence of genuine alprazolam, frequently revealing substitute active ingredients including potent novel synthetic designer benzodiazepines (e.g., bromazolam, flubromazepam, clonazolam) or lethal synthetic opioids (such as nitazene analogues).

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Trankimazin 2mg is driven by potent, stereospecific positive allosteric modulation of inhibitory neurotransmission across the central nervous system:

• Positive Allosteric Modulation of the $GABA_A$ Complex: Alprazolam binds to the high-affinity benzodiazepine recognition pocket situated at the interface between the $\alpha$ ($\alpha_1$, $\alpha_2$, $\alpha_3$, or $\alpha_5$) and $\gamma_2$ subunits of the pentameric $\gamma\text{-aminobutyric acid type A}$ ($GABA_A$) ligand-gated chloride channel.

• Chloride Conductance and Hyperpolarization: It exhibits no direct intrinsic agonist properties at clinical concentrations (it cannot gate the channel in the absence of endogenous GABA). When endogenous GABA occupies its orthosteric sites, alprazolam induces an allosteric conformational shift that increases the frequency of chloride channel opening bursts. The resulting influx of extracellular chloride ions ($Cl^-$) down an electrochemical gradient hyperpolarizes the postsynaptic neuronal membrane, stabilizing the resting membrane potential below firing threshold and attenuating action potential propagation across limbic, cortical, and subcortical pathways.

• Subunit-Mediated Pharmacodynamics:

  • $\alpha_1$ Subunit Interactions: Predominantly located in the cerebral cortex and cerebellum; mediates sedative-hypnotic actions, anterograde amnesia, and ataxia.

  • $\alpha_2$ und $\alpha_3$ Subunit Interactions: Concentrated in the amygdala, limbic networks, and spinal motor neurons; responsible for alprazolam’s potent anxiolytic, anti-panic, and muscle-relaxant properties.

  • $\alpha_5$ Subunit Interactions: Localized primarily within the hippocampus; mediates spatial memory disruption and cognitive fragmentation.

• Relative Potency and HPA Axis Suppression: Alprazolam is a high-potency agent: $0.5\text{ mg}$ of oral alprazolam is clinically bioequivalent to approximately $10\text{ mg}$ of oral diazepam (making a single 2mg Trankimazin bar equivalent to $\sim 40\text{ mg}$ of diazepam). Alprazolam uniquely suppresses the hypothalamic-pituitary-adrenal (HPA) axis, rapidly blunting adrenocorticotropic hormone (ACTH) and cortisol secretion during acute, severe panic paroxysms.

3. Approved UK and European Clinical Indications and Therapeutic Scope

Trankimazin holds licensed therapeutic indications within European clinical guidelines, whereas UK clinical practice strictly limits its use:

• Licensed European Indications (AEMPS / EMA):

  • Severe, Disabling Anxiety States: Short-term management of generalized anxiety disorder (GAD) when symptoms are severe, incapacitating, or subjecting the individual to extreme distress.

  • Panic Disorder with or without Agoraphobia: Short-term alleviation of acute panic attacks and associated phobic avoidance.

• Prescribing Duration Restrictions: European and UK clinical safety guidelines mandate that treatment be restricted to the lowest effective dose for a maximum duration of 2 to 4 weeks, inclusive of a mandatory gradual tapering phase. Long-term, continuous prescribing is contraindicated due to rapid physiological tolerance and dependence.

The National Institute for Health and Care Excellence (NICE) provides clinical management guidelines for anxiety and panic disorders (CG113). NICE explicitly advises against the long-term use of benzodiazepines for generalized anxiety disorder and panic disorder, noting the absence of demonstrated long-term efficacy and significant liabilities of cognitive blunting, dependence, and rebound exacerbation. NICE positions SSRIs, SNRIs, and structured cognitive behavioral therapy (CBT) as first-line therapies.

In unauthorized and non-medical contexts, Trankimazin 2mg is widely misused:

• Rapid termination of psychostimulant-induced hyperarousal (“comedowns” following cocaine, amfetamines, MDMA, or synthetic cathinones).

• Recreational intoxication sought for profound emotional detachment, chemical anxiolysis, and disinhibition.

• Polysubstance stacking with alcohol or opioids.

Trankimazin holds no listing on the NHS Drug Tariff, cannot be reimbursed via NHS prescription forms (FP10), and must be treated as an imported controlled pharmaceutical when encountered in clinical practice.

4. Pharmacokinetic Profile and Metabolic Fate

Because Trankimazin 2mg is an immediate-release oral solid formulation, its disposition is characterized by rapid gastrointestinal absorption, intermediate systemic clearance, and predominant hepatic biotransformation:

• Absorption: Following oral administration, alprazolam is rapidly and almost completely absorbed across the gastrointestinal tract. Peak plasma concentrations ($C_{max}$) are achieved within 1 to 2 hours (median $T_{max} \approx 1.5\text{ hours}$). Absolute oral bioavailability is high, averaging $80\text{ to }90\%$. High-fat meals minimally impact overall exposure ($AUC$), but can delay peak absorption by up to an hour.

• Distribution: Alprazolam displays moderate lipophilicity, penetrating the blood-brain barrier rapidly to produce prompt central effects. Its apparent volume of distribution ($V_d$) ranges between $0.8\text{ and }1.2\text{ L/kg}$. In circulating plasma, it is approximately $70\text{ to }80\%$ bound to serum proteins, primarily human serum albumin. It crosses the placental boundary freely and concentrates in maternal breast milk.

• Biotransformation: Clearance is mediated almost entirely by hepatic microsomal oxidation via the cytochrome P450 3A4 (CYP3A4) und CYP3A5 isoenzymes:

  • Phase I Hydroxylation: CYP3A4 converts alprazolam into two primary active metabolites: $\alpha\text{-hydroxyalprazolam}$ und $4\text{-hydroxyalprazolam}$. While $\alpha\text{-hydroxyalprazolam}$ retains approximately $50\%$ of the parent drug’s biological potency, its circulating plasma concentrations are low ($<10\%$ of parent levels), meaning clinical effects are driven primarily by parent alprazolam.

  • Phase II Conjugation: Hydroxylated metabolites undergo rapid glucuronidation via hepatic UDP-glucuronosyltransferases (UGTs) into inactive, water-soluble glucuronide conjugates.

• Elimination: Systemic elimination is predominantly renal, with approximately $80\%$ of an administered dose excreted in the urine as polar metabolites, and less than $20\%$ eliminated as unchanged drug. The mean terminal elimination half-life ($t_{1/2}$) of alprazolam in healthy young adults averages 11 to 15 hours (range: 8 to 20 hours). The half-life is significantly prolonged in elderly individuals (mean $t_{1/2} \approx 16\text{ hours}$), patients with severe hepatic cirrhosis ($t_{1/2} > 25\text{ hours}$), and obese patients. Due to its intermediate half-life and absence of long-lived active metabolites, chronic dependent users characteristically experience inter-dose withdrawal phenomena, marked by rebound panic, tremors, and severe anxiety between scheduled daily doses.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect in authorized clinical practice is rapid attenuation of central autonomic and somatic hyperarousal. However, high-affinity $GABA_A$ positive modulation across cortical and subcortical pathways produces a broad spectrum of multi-system adverse effects:

• Neuropsychiatric and Cognitive Impairment (Very Common, $\ge 1/10$):

  • Drowsiness, daytime somnolence, cognitive clouding, and profound fatigue.

  • Anterograde amnesia: acute failure to consolidate short-term declarative memories into long-term storage, frequently leading to drug-induced “blackouts” at elevated doses.

  • Paradoxical reactions: unexpected behavioral disinhibition, acute psychomotor agitation, hostility, rage, emotional volatility, and hallucinations (disproportionately observed in elderly, pediatric, or psychiatric cohorts).

• Neuromuscular and Sensorimotor Disruptions (Common, $1/100$ to $<1/10$):

  • Cerebellar ataxia, loss of motor coordination, unsteady gait, and dysarthria (slurred speech), substantially elevating the risk of mechanical falls, head trauma, and fractures.

  • Muscle flaccidity, dizziness, and lightheadedness.

• Severe, Emergent and Life-Threatening Hazards (Rare to Polysubstance Toxicity):

  • Synergistic Respiratory Depression and Fatal Hypoxia: In isolation, pure alprazolam overdose rarely results in fatal central apnea in healthy adults; however, co-administration with other central nervous system depressants (especially opioids, alcohol, or sedating antihistamines) is lethal. Synergistic suppression of brainstem medullary respiratory centers induces profound hypoventilation, hypercapnic hypoxia, coma, and fatal asphyxiation.

  • Rapid Physical Dependence and Severe Withdrawal Syndrome: Continuous exposure for as little as 2 to 3 weeks triggers rapid neuroadaptation, marked by uncoupling and down-regulation of $GABA_A$ receptors and compensatory hyper-sensitization of glutamatergic (NMDA/AMPA) pathways. Abrupt discontinuation precipitates a life-threatening withdrawal syndrome:

    • Rebound anxiety, agoraphobia, panic attacks, and severe insomnia.

    • Autonomic hyperactivity: sinus tachycardia, malignant hypertension, hyperthermia, and profuse diaphoresis.

    • Delirium tremens, visual/auditory/tactile hallucinations, depersonalization, and unprovoked violent agitation.

    • Status Epilepticus: Grand mal seizures typically manifest within 24 to 72 hours of abrupt cessation; prolonged or recurring status epilepticus carries high risks of permanent hypoxic brain injury, rhabdomyolysis, and death if not emergently treated.

  • Pulmonary Aspiration: Profound drug-induced stupor accompanied by emesis carries high risks of chemical pneumonitis and fatal airway obstruction due to blunted protective pharyngeal reflexes.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, administering, or evaluating individuals exposed to Trankimazin 2mg requires strict adherence to pharmacological contraindications, drug-interaction screening, and harm-minimisation standards:

• Contraindications:

  • Severe Respiratory Insufficiency: Absolute contraindication in acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), or decompensated respiratory failure.

  • Myasthenia Gravis: Absolute contraindication; intrinsic skeletal muscle-relaxant actions can precipitate fatal respiratory muscle paralysis.

  • Sleep Apnea Syndrome: Contraindicated due to the risk of exacerbating severe nocturnal hypoxia and prolonged central obstructive apneas.

  • Severe Hepatic Impairment: Contraindicated in advanced cirrhosis or acute liver failure due to impaired CYP3A4 clearance, prolonged drug accumulation, and the precipitating risk of hepatic encephalopathy.

  • Concurrent Potent CYP3A4 Inhibitors: Co-administration with strong systemic azole antifungals (e.g., ketoconazole, itraconazole) is absolutely contraindicated.

  • Pregnancy and Lactation: Absolute contraindication; crosses the placenta, risks congenital malformations, causes neonatal “floppy infant syndrome” (hypothermia, hypotonia, respiratory distress), and precipitates neonatal withdrawal; concentrates in maternal breast milk.

  • Paediatric Population: Contraindicated in children and adolescents under 18 years of age.

• Drug Interactions:

  • Opioids (e.g., Morphine, Oxycodone, Methadone, Buprenorphine, Fentanyl): Major synergistic hazard; profound, potentially fatal depression of the medullary ventilatory drive. Co-prescribing requires rigorous clinical justification, minimum dosing, and close monitoring.

  • Ethanol (Alcohol): Synergistically amplifies $GABA_A$ receptor chloride conductance, producing rapid loss of consciousness, profound amnesia, fatal respiratory arrest, and elevated trauma risks.

  • Potent Cytochrome P450 3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Ritonavir, Nefazodone, Grapefruit Juice): Markedly blocks alprazolam clearance, increasing plasma $AUC$ by up to $200\text{ to }400\%$ and tripling the elimination half-life, predisposing to profound, prolonged toxicity.

  • CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates clearance, reducing systemic alprazolam concentrations and triggering breakthrough panic or acute withdrawal in dependent individuals.

• Clinical Precautions and Harm Minimisation:

  • Acute Overdose Management (“Red Flags”): Patients presenting to emergency departments (999/A&E) with profound stupor, central hypoventilation, airway compromise, or unresponsiveness require immediate stabilization:

    • Airway and Ventilatory Support: Maintain airway patency, position in the lateral recovery position, provide high-flow oxygen, and support ventilation with bag-valve-mask or endotracheal intubation if respiratory depression is present.

    • Judicious Use of Flumazenil: The specific $GABA_A$ antagonist flumazenil ($0.2\text{ mg}$ IV slowly, titrated up to $1.0\text{ mg}$) is available in hospital settings, but must be used with extreme caution. It is strictly contraindicated in patients with mixed overdoses (especially involving pro-convulsant drugs like tricyclic antidepressants) or in individuals with chronic benzodiazepine tolerance, as acute receptor displacement can precipitate intractable, life-threatening status epilepticus.

  • Structured Discontinuation and Detoxification Protocols: Trankimazin 2mg must never be discontinued abruptly in chronic users. Due to its short half-life and potency, successful detoxification requires cross-tapering to an equivalent dose of a long-acting, licensed pharmaceutical agent—specifically oral diazepam (where $2\text{ mg}$ alprazolam equates to $\sim 40\text{ mg}$ diazepam)—followed by a slow, gradual dose reduction (e.g., reducing by $1\text{ to }2\text{ mg}$ of diazepam equivalent every 1 to 2 weeks) under structured medical supervision.

  • Counterfeit Sourcing Warnings: Healthcare professionals encountering individuals taking black-market “Trankimazin 2mg” bars acquired online or on the street must clearly communicate that illicit supplies routinely contain novel synthetic designer benzodiazepines (e.g., bromazolam) or synthetic nitazene opioids, carrying critical, unpredictable risks of fatal poisoning.

Weitere Informationen